Fluorescence nanozyme B-CDs@SiO2@MnO2 for the dual-mode immunoassay of cardiac troponin I
Analytical and Bioanalytical Chemistry · 2026-03 · 418 (5) · 1517-1529
DOI: 10.1007/s00216-026-06313-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical and Bioanalytical Chemistry, online erschienen am 16.01.2026. Verfasst von Li Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Key Laboratory of Functional Molecular Solids, Ministry of Education; Anhui Key Laboratory of Biomedical Materials and Chemical Measurement; Coll…. Hauptthemen laut MEDLINE: Manganese Compounds, Oxides, Silicon Dioxide, Troponin I. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: University Synergy Innovation Program of Anhui Province, National Natural Science Foundation of China, Health Research Program of Anhui.
Abstract (Originalsprache)
Acute myocardial infarction (AMI) poses a severe threat to human health, making its rapid and sensitive diagnosis crucial. Cardiac troponin I (cTnI) has been established as the gold standard biomarker for AMI diagnosis. Herein, a dual-mode immunosensor was constructed by integrating manganese dioxide (MnO2) nanozyme and fluorescence carbon dot (B-CDs) in silica (SiO2), termed B-CDs@SiO2@MnO2, for the colorimetric and fluorescent detection of cTnI. The sensing signal mainly included two parts: B-CDs@SiO2@MnO2-based catalytic color reaction and B-CDs@SiO2 fluorescence recovery after etching MnO2. The MnO2 nanozyme catalyzes the oxidation of TMB to generate blue-colored TMBox, which turns yellow upon acid addition, enabling colorimetric detection. Concurrently, the MnO2 nanosheets quench the fluorescence of B-CDs@SiO2. In the presence of ascorbic acid (AA), MnO2 is reduced to Mn2+, leading to fluorescence recovery and thus enabling fluorescent detection. Profiting from the superior self-correction features of B-CDs@SiO2@MnO2 dual-mode sensor, this method exhibits good linearity and sensitivity toward cTnI among 0.05-50 ng/mL, with detection limits of 0.0074 ng/mL for the colorimetric mode and 0.0063 ng/mL for the fluorescent mode. In addition, the human serum samples' recoveries show good agreement between the colorimetric mode (90.0-117.8%) and the fluorescent mode (90.2-115.8%). Furthermore, we employ this platform to monitor cTnI levels in both cellular and blood samples from AMI patients, indicating the promising clinical application potential of this platform.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Key Laboratory of Functional Molecular Solids, Ministry of Education; Anhui Key Laboratory of Biomedical Materials and Chemical Measurement; College of Chemistry and Materials Science, Anhui Normal University, Wuhu,…
- Anhui Province Key Laboratory of Non-Coding RNA Basic and Clinical Transformation; Central Laboratory, Yijishan Hospital, The First Affiliated Hospital of Wannan Medical College, Wuhu, 241001, P.R. China.
Förderung
- University Synergy Innovation Program of Anhui Province
- National Natural Science Foundation of China
- Health Research Program of Anhui
- Key Projects of Natural Science Research of Universities in Anhui Province
- Natural Science Foundation of Anhui Province
Zitieren
APA
Wang, L., Li, L., Chen, W., & Zhang, M. (2026). Fluorescence nanozyme B-CDs@SiO2@MnO2 for the dual-mode immunoassay of cardiac troponin I. Analytical and Bioanalytical Chemistry, 418(5), 1517-1529. https://doi.org/10.1007/s00216-026-06313-8
Vancouver
Wang L, Li L, Chen W, Zhang M. Fluorescence nanozyme B-CDs@SiO2@MnO2 for the dual-mode immunoassay of cardiac troponin I. Analytical and Bioanalytical Chemistry. 2026;418(5):1517-1529. doi:10.1007/s00216-026-06313-8
BibTeX
@article{Wang2026,
author = {Wang, Li and Li, Lei and Chen, Wei and Zhang, Mingcui},
title = {Fluorescence nanozyme B-CDs@SiO2@MnO2 for the dual-mode immunoassay of cardiac troponin I},
journal = {Analytical and Bioanalytical Chemistry},
year = {2026},
volume = {418},
number = {5},
pages = {1517--1529},
doi = {10.1007/s00216-026-06313-8}
}
EUVIMED